SG10201906474QA - Compositions and methods for the treatment of mucositis - Google Patents

Compositions and methods for the treatment of mucositis

Info

Publication number
SG10201906474QA
SG10201906474QA SG10201906474QA SG10201906474QA SG10201906474QA SG 10201906474Q A SG10201906474Q A SG 10201906474QA SG 10201906474Q A SG10201906474Q A SG 10201906474QA SG 10201906474Q A SG10201906474Q A SG 10201906474QA SG 10201906474Q A SG10201906474Q A SG 10201906474QA
Authority
SG
Singapore
Prior art keywords
formula
treatment
mucositis
compositions
oral
Prior art date
Application number
SG10201906474QA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG10201906474QA publication Critical patent/SG10201906474QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Abstract

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS The invention relates to the compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII, and methods for the treatment of mucositis may be formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral and gastrointestinal mucositis, mucosal inflammatory and oral infectious diseases. Figure for publication: None
SG10201906474QA 2015-02-09 2016-01-19 Compositions and methods for the treatment of mucositis SG10201906474QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN622CH2015 2015-02-09

Publications (1)

Publication Number Publication Date
SG10201906474QA true SG10201906474QA (en) 2019-09-27

Family

ID=55640795

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706369PA SG11201706369PA (en) 2015-02-09 2016-01-19 Compositions and methods for the treatment of mucositis
SG10201906474QA SG10201906474QA (en) 2015-02-09 2016-01-19 Compositions and methods for the treatment of mucositis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201706369PA SG11201706369PA (en) 2015-02-09 2016-01-19 Compositions and methods for the treatment of mucositis

Country Status (6)

Country Link
EP (1) EP3256459B1 (en)
JP (1) JP6698669B2 (en)
CN (1) CN107873024A (en)
CA (1) CA2976187A1 (en)
SG (2) SG11201706369PA (en)
WO (1) WO2016128991A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007713A (en) * 2016-12-26 2019-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of chronic pain.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (en) * 1963-08-09
JPS4832868A (en) * 1971-08-27 1973-05-02
ES447306A1 (en) * 1976-04-23 1977-07-01 Liade Sa Lab Procedure for obtaining a derivative of 1-benzoyl-3- (dimethylamino) propoxy) -1H-indazol. (Machine-translation by Google Translate, not legally binding)
JPS61129124A (en) * 1984-11-28 1986-06-17 Kureha Chem Ind Co Ltd Antitumor agent
AU610839B2 (en) * 1986-11-07 1991-05-30 Purepac, Inc Transdermal administration of amines
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
CA2009402A1 (en) * 1990-02-06 1991-08-06 Attilio J. De Sanctis Use of benzydamine and salts thereof for relief of pain associated with herpes viral infections and laser vaporization of condylomata
IT1274026B (en) * 1994-03-01 1997-07-14 Acraf ANTITOSSE COMPOSITION
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
JP4395200B2 (en) 1997-10-28 2010-01-06 バンドー化学株式会社 Skin patch sheet and method for producing substrate sheet therefor
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (en) 1998-06-22 1999-12-23 Rottapharm Bv Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
CN101219139A (en) * 2007-12-24 2008-07-16 广西壮族自治区花红药业股份有限公司 benzydamine Hcl suppository and method for preparing the same
KR101723996B1 (en) * 2009-07-08 2017-04-06 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
CN103893171B (en) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 The application of benzydamine hydrochloride in preparation treatment or flu-prevention virus infective medicament

Also Published As

Publication number Publication date
CA2976187A1 (en) 2016-08-18
EP3256459A1 (en) 2017-12-20
NZ735338A (en) 2021-08-27
SG11201706369PA (en) 2017-09-28
CN107873024A (en) 2018-04-03
JP2018504439A (en) 2018-02-15
EP3256459B1 (en) 2022-07-13
WO2016128991A1 (en) 2016-08-18
JP6698669B2 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
NZ766570A (en) Pyrimidinones as factor xia inhibitors
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
PH12015502055A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
MX2020011449A (en) Oxysterols and methods of use thereof.
MY197698A (en) Oxysterols and methods of use thereof
IN2014CN02364A (en)
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2019003912A (en) Compositions and methods for the treatment of xerostomia.
NZ701832A (en) Compositions and methods for treatment of inflammatory bowel disease
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
MX2019000279A (en) Compositions and methods for the treatment of cancer.
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
CY1121063T1 (en) INHIBITORS OF ALDOSTERONE COMPOSITION
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MX2019006163A (en) Compositions and methods for the treatment of oral infectious diseases.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
MX2019001360A (en) Compositions and methods for the treatment of irritable bowel syndrome.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease